Calidi Biotherapeutics (CLDI) Competitors $1.05 -0.21 (-16.67%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.06 +0.01 (+0.95%) As of 02/21/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends CLDI vs. PBYI, SLDB, BMEA, CHRS, MCRB, TELO, TIL, KYTX, TSVT, and BDTXShould you be buying Calidi Biotherapeutics stock or one of its competitors? The main competitors of Calidi Biotherapeutics include Puma Biotechnology (PBYI), Solid Biosciences (SLDB), Biomea Fusion (BMEA), Coherus BioSciences (CHRS), Seres Therapeutics (MCRB), Telomir Pharmaceuticals (TELO), Instil Bio (TIL), Kyverna Therapeutics (KYTX), 2seventy bio (TSVT), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry. Calidi Biotherapeutics vs. Puma Biotechnology Solid Biosciences Biomea Fusion Coherus BioSciences Seres Therapeutics Telomir Pharmaceuticals Instil Bio Kyverna Therapeutics 2seventy bio Black Diamond Therapeutics Calidi Biotherapeutics (NYSE:CLDI) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, community ranking, dividends, risk, earnings, media sentiment and valuation. Is CLDI or PBYI more profitable? Puma Biotechnology has a net margin of 9.56% compared to Calidi Biotherapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 41.60% beat Calidi Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Calidi BiotherapeuticsN/A N/A -344.45% Puma Biotechnology 9.56%41.60%10.71% Does the media favor CLDI or PBYI? In the previous week, Puma Biotechnology had 1 more articles in the media than Calidi Biotherapeutics. MarketBeat recorded 1 mentions for Puma Biotechnology and 0 mentions for Calidi Biotherapeutics. Calidi Biotherapeutics' average media sentiment score of 0.00 equaled Puma Biotechnology'saverage media sentiment score. Company Overall Sentiment Calidi Biotherapeutics Neutral Puma Biotechnology Neutral Does the MarketBeat Community believe in CLDI or PBYI? Puma Biotechnology received 551 more outperform votes than Calidi Biotherapeutics when rated by MarketBeat users. CompanyUnderperformOutperformCalidi BiotherapeuticsN/AN/APuma BiotechnologyOutperform Votes55167.11% Underperform Votes27032.89% Which has more risk and volatility, CLDI or PBYI? Calidi Biotherapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Do analysts rate CLDI or PBYI? Calidi Biotherapeutics presently has a consensus price target of $16.67, indicating a potential upside of 1,487.30%. Puma Biotechnology has a consensus price target of $7.00, indicating a potential upside of 141.38%. Given Calidi Biotherapeutics' higher possible upside, analysts plainly believe Calidi Biotherapeutics is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in CLDI or PBYI? 12.5% of Calidi Biotherapeutics shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 24.3% of Calidi Biotherapeutics shares are held by company insiders. Comparatively, 23.7% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger valuation & earnings, CLDI or PBYI? Puma Biotechnology has higher revenue and earnings than Calidi Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalidi Biotherapeutics$50K555.66-$29.22MN/AN/APuma Biotechnology$235.60M0.60$21.59M$0.486.04 SummaryPuma Biotechnology beats Calidi Biotherapeutics on 8 of the 13 factors compared between the two stocks. Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDI vs. The Competition Export to ExcelMetricCalidi BiotherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$27.78M$3.12B$5.77B$20.07BDividend YieldN/A1.57%4.78%3.65%P/E RatioN/A30.1126.4634.89Price / Sales555.66412.67456.6715.65Price / CashN/A183.5344.0420.85Price / Book-0.453.567.634.92Net Income-$29.22M-$71.72M$3.18B$1.02B7 Day Performance-22.79%-2.46%-1.91%-1.05%1 Month Performance37.43%-0.25%-0.19%-1.09%1 Year PerformanceN/A-12.31%16.70%13.71% Calidi Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDICalidi Biotherapeutics1.9905 of 5 stars$1.05-16.7%$16.67+1,487.3%N/A$33.34M$50,000.000.0038Gap UpPBYIPuma Biotechnology3.7611 of 5 stars$2.80+0.6%$7.00+150.3%-55.5%$137.30M$243.57M5.83200Upcoming EarningsNews CoverageSLDBSolid Biosciences4.0798 of 5 stars$3.44+19.3%$15.30+345.4%-42.4%$137.25M$8.09M-1.13100Analyst ForecastAnalyst RevisionNews CoverageGap UpHigh Trading VolumeBMEABiomea Fusion3.3375 of 5 stars$3.76+0.2%$39.36+947.2%-77.4%$136.23MN/A-0.9450Positive NewsCHRSCoherus BioSciences3.6681 of 5 stars$1.18+4.9%$5.38+357.4%-56.9%$136.17M$257.24M-14.69330MCRBSeres Therapeutics3.9958 of 5 stars$0.80+1.8%$5.08+538.6%-23.5%$135.91M$126.33M-3.46330News CoverageTELOTelomir Pharmaceuticals2.2818 of 5 stars$4.45+1.8%N/A-54.8%$132.34MN/A-7.671Analyst ForecastNews CoverageTILInstil Bio2.9407 of 5 stars$20.03-3.8%$114.00+469.1%+88.3%$130.72MN/A-1.73410News CoveragePositive NewsKYTXKyverna Therapeutics1.1479 of 5 stars$3.02+0.5%$25.71+752.9%-89.9%$130.16M$7.03M0.0096TSVT2seventy bio2.1813 of 5 stars$2.46+6.7%$7.20+193.3%-53.2%$126.65M$100.39M-1.32440Analyst ForecastNews CoverageBDTXBlack Diamond Therapeutics3.3805 of 5 stars$2.24-9.1%$15.50+593.5%-53.7%$126.46MN/A-1.6890Short Interest ↓ Related Companies and Tools Related Companies Puma Biotechnology Competitors Solid Biosciences Competitors Biomea Fusion Competitors Coherus BioSciences Competitors Seres Therapeutics Competitors Telomir Pharmaceuticals Competitors Instil Bio Competitors Kyverna Therapeutics Competitors 2seventy bio Competitors Black Diamond Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CLDI) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
